️ Episode 146: Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA in Solid Tumors

In this episode of PaperCast Base by Base, we explore the clinical feasibility of an automated and decentralized cfDNA sequencing system designed to identify actionable and resistance alterations in advanced solid tumors.

Study Highlights:
Researchers evaluated plasma cfDNA from 298 patients with advanced cancers using the Oncomine Precision Assay GX and Genexus integrated sequencer. Sequencing success rates were higher for cfDNA compared to tumor tissue, and 50% of patients had detectable ctDNA mutations. Concordance between plasma and tumor results reached 72%, with detection influenced by tumor type, burden, and metastatic site. Plasma-only alterations were observed in 18% of patients, particularly in those previously treated with targeted therapies, underscoring cfDNA’s role in capturing tumor evolution.

Conclusion:
This decentralized approach demonstrates strong potential for expanding timely genomic profiling and improving access to precision oncology.

Reference:
Chan HT, Otaki M, Hayashi N, Fukada I, Chin YM, Fukuda N, Hosonaga M, Wang X, Yunokawa M, Shinozaki E, Yamaguchi K, Wakatsuki T, Kasuga A, Nakamura Y, Takahashi S, Low SK. Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors. Clinical Chemistry. 2025;71(6):700-712. https://doi.org/10.1093/clinchem/hvaf045

License:
This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/

Support:
If you'd like to support Base by Base, you can make a one-time or monthly donation here: https://basebybase.castos.com/